SUSTAINED NANO SYSTEMS, LLC

small answers to big problems

WHO WE ARE

Clinical Leadership

Barry Libin, DDS, MSD, MS – Founder & CEO

Dr. Libin is responsible for the daily operations of the Company.  He is an experienced researcher and businessman in taking companies from inception through the development stages. He was Founder, Chairman and CEO of BML Pharmaceuticals Inc., a pharmaceutical research and development company in inflammatory and infectious diseases. Dr. Libin identified, formulated and directed clinical studies on a series of drugs having anti-inflammatory (Cox 2), anti-microbial and analgesic properties. BML’s lead drug in cancer therapy for prevention of chemotherapy and radiation induced mucositis was granted fast track status by the FDA and advanced through phase three clinical testing before BML was sold to Endo Pharmaceuticals in July of 2002. Following that Dr. Libin founded BML MedRecords Alert, LLC, an electronic medical records company that provides hospitals and physicians with “paperless” venues, and provides individual consumers with secure personal medical vaults. Dr. Libin received his DDS and his Masters (MSD) in Periodontics and Oral Medicine from NYU College of Dentistry, and his MS in Management and Policy from the Harriman School of Business at the State University at Stony Brook.

Jeffrey M. Liebmann, MD – Ophthalmology Program

Dr. Liebmann is Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center. Dr. Liebmann graduated from Boston University’s Combined Six-Year Medical Education Program in 1983, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and glaucoma fellowship training at the New York Eye and Ear Infirmary. Dr. Liebmann was previously Clinical Professor of Ophthalmology at New York University School of Medicine and Director of Glaucoma Services at Manhattan Eye, Ear, and Throat Hospital and New York University Langone Medical Center. Dr. Liebmann is the immediate past-President of the World Glaucoma Association, past-President of the American Glaucoma Society, Secretary-Treasurer of the New York Glaucoma Society, and co-editor of Journal of Glaucoma and is a member of the Board of Governors of the World Glaucoma Association and Boards of Directors of The Glaucoma Foundation and the American Glaucoma Society Foundation. In addition to having one of the nation’s busiest tertiary-care glaucoma practices, Dr. Liebmann is also the Principal Investigator of the African Descent and Glaucoma Evaluation Study and is the author and/or co-author of more than 1,000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

Weiliam Chen B.S., M.S., Ph.D. – Chief Scientific Officer

Dr. Chen is a leading expert in biodegradable polymer matrices for drug and gene delivery and tissue engineering. Dr. Chen received his B.S. in Pharmacy from the University of Wisconsin, and his M.S. and Ph.D. from the University of Michigan in Pharmaceutics. Dr. Chen was Associate Professor of BioMedical Engineering in the Department of Surgery at New York University and past Associate Professor in the Department of Biomedical Engineering at the State University of New York at Stony Brook, where he jointly Co-founded EndoMedix, Inc., in the Long Island High Technology Incubator. Prior to that he was Manager of Drug/Gene Delivery Technologies at Clear Solutions (2001-2003). He has been awarded numerous grants from the NIH in the fields of biodegradable drug delivery devices and tissue engineering. He has written numerous peer reviewed articles and has lectured throughout the world.

David Beach, B.S., Ph.D. – Director of Operations

Dr. Beach received his BS in Pharmacy at Union University-Albany College of Pharmacy and his Ph.D. at the University of Maryland. He is past President and COO of Synovics Pharmaceuticals where he was responsible for overall operations, including Prescription and Business Development. Previously he was Senior Consultant to VCG&A in Toronto where he managed the Phase II Clinical Program, and at Genpharm where he was Director of Research and Development. Dr. Beach was Associate Director of Pharmaceutical Process Improvement at Schering-Plough and Solids Development Senior Scientist/Group Leader at DuPont Pharmaceuticals.

Jan Peterson, M.S., Biomedical Sciences – Director, Regulatory Affairs

As Senior Regulatory Affairs Director, Jan is responsible for overall relationships with the FDA. He has over 40 years of experience in clinical research trial design and regulatory affairs, including Director of Regulatory Affairs at Emmes for numerous clinical trials. Mr. Peterson is the 2018 Chair of the Association of Clinical Research Professionals (ACRP) Regulatory Affairs Committee. He received his BA in Biomedical Sciences from St. Cloud State University (MN) and an MS in Pharmacology and Experimental Therapeutics from the University of California at San Francisco.

David Boyer, M.D. – Ophthalmology, Retinal Advisory Board

David Boyer, M.D., is a world-renowned clinician, surgeon, and educator. He received a Bachelor of Science Degree from the University of Illinois at Champaign, IL, a medical degree at the Chicago Medical School, residency at the Los Angeles County -USC County Medical Center, and retinal surgery fellowship at the Wills Eye Hospital, in Philadelphia. He is currently a leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple research, educational and charitable institutions.

Peter K. Kaiser, M.D. – Ophthalmology, Retinal Advisory Board

Peter K. Kaiser, MD, is with the vitreoretinal faculty of the Cole Eye Institute in the Department of Ophthalmology at the Cleveland Clinic and Founding Director of their Digital Optical Coherence Tomography (OCT) Reading Center. He received his medical degree magna cum laude from Harvard Medical School, internship in internal medicine at Massachusetts General Hospital, ophthalmology residency at the Massachusetts Eye and Ear Infirmary and a retinal fellowship at Bascom Palmer Eye Institute in Miami, Florida. Dr. Kaiser is study chairman of 4 major, multi-center, international clinical trials. He has authored several ophthalmology texts, and more than 200 publications. He is an associate editor of the American Journal of Ophthalmology, and serves on the editorial boards of Retina, Retina Today, Retinal Physician and Ocular Surgery News. Dr. Kaiser is the team ophthalmologist for the Cleveland Browns, Cleveland Cavaliers and the Cleveland Indians.

Uri R. Shabto, MD – Ophthalmology, Retinal Advisory Board

Uri R. Shabto, M.D., is a leading specialist in retinal disease. Dr. Shabto graduated Cum Laude from Columbia University and received his M.D. from the Harvard Medical School. He completed an internship in Internal Medicine at The Lenox Hill Hospital, and a residency in Ophthalmology at the New York Eye and Ear Infirmary where he also served as Chief resident. He is fellowship trained in Retina-Vitreous diseases completing that training at Montefiore Medical Center in New York. Dr. Shabto is a past Associate Professor of Ophthalmology at New York Medical College, and senior attending on the Retina and Trauma service at the New York Eye & Ear Infirmary. He has authored numerous publications in ophthalmology and retinal disease. Prior to joining SNS, Dr. Shabto was founder, president and CEO of the Retina Consultants of New York, one of the largest retinal practices in the U.S. Dr. Shabto is a member of the American Academy of Ophthalmology and a diplomate of the American Board of Ophthalmology.

Morton Coleman, B.A., M.D. – Director, Medical Oncology Advisory Board

Dr. Coleman is Clinical Professor of Medicine at New York Presbyterian Hospital and Diplomate in Hematology and Oncology of the American Board of Internal Medicine. He is Associate Director of the Division of Hematology-Oncology and Director of the Center for Lymphoma and Myeloma, at New York Presbyterian-Weill Cornell Medical Center. Dr. Coleman is Associate Editor of the Journal of Clinical Lymphoma, Myeloma & Leukemia, and authored nearly 300 scientific articles, books, and reviews. He received his B.A. from Johns Hopkins University, M.D. from the Medical College of Virginia School of Medicine, and a Fellowship in Hematology at the National Institutes of Health. Dr. Coleman’s expertise is in the treatment of lymphoma, myeloma, Waldenstrom’s macroglobulinemia, and associated diseases. He is a leader in the innovative applications of monoclonal antibodies in lymphoma and has played an instrumental role in devising the standard treatment for Hodgkin’s disease, the use of infusional chemotherapy in lymphoma, the concept of dose intensity and its use in myeloma and lymphoma, the combined use of thalidomide in myeloma, and the role of PET scanning in lymphoma.

Corporate Leadership – Board of Directors

 Barry Libin, DDS, MSD, MS – Founder & CEO

Chairman of the Board.

Dr. Libin is responsible for the daily operations of the Company.  He is an experienced researcher and businessman in taking companies from inception through the development stages. He was Founder, Chairman and CEO of BML Pharmaceuticals Inc., a pharmaceutical research and development company in inflammatory and infectious diseases. Dr. Libin identified, formulated and directed clinical studies on a series of drugs having anti-inflammatory (Cox 2), anti-microbial and analgesic properties. BML’s lead drug in cancer therapy for prevention of chemotherapy and radiation induced mucositis was granted fast track status by the FDA and advanced through phase three clinical testing before BML was sold to Endo Pharmaceuticals in July of 2002. Following that Dr. Libin founded BML MedRecords Alert, LLC, an electronic medical records company that provides hospitals and physicians with “paperless” venues, and provides individual consumers with secure personal medical vaults. Dr. Libin received his DDS and his Masters (MSD) in Periodontics and Oral Medicine from NYU College of Dentistry, and his MS in Management and Policy from the Harriman School of Business at the State University at Stony Brook.

Jeffrey M. Liebmann, MD – Ophthalmology Program

Member, Board of Directors

Dr. Liebmann is Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center. Dr. Liebmann graduated from Boston University’s Combined Six-Year Medical Education Program in 1983, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and glaucoma fellowship training at the New York Eye and Ear Infirmary. Dr. Liebmann was previously Clinical Professor of Ophthalmology at New York University School of Medicine and Director of Glaucoma Services at Manhattan Eye, Ear, and Throat Hospital and New York University Langone Medical Center. Dr. Liebmann is the immediate past-President of the World Glaucoma Association, past-President of the American Glaucoma Society, Secretary-Treasurer of the New York Glaucoma Society, and co-editor of Journal of Glaucoma and is a member of the Board of Governors of the World Glaucoma Association and Boards of Directors of The Glaucoma Foundation and the American Glaucoma Society Foundation. In addition to having one of the nation’s busiest tertiary-care glaucoma practices, Dr. Liebmann is also the Principal Investigator of the African Descent and Glaucoma Evaluation Study and is the author and/or co-author of more than 1,000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

Cadmus Rich, M.D. – Ophthalmology, Member, Board of Directors

Dr. Rich has 15 years of Research and Development in product and clinical development, including strategic, regulatory and clinical planning, clinical operations/CRO relationships and managing programs. Dr. Rich has participated or led over 50 product development programs and/or clinical development projects including over 120 clinical trials with over 80 clinical and preclinical studies in ophthalmology and approximately 50 studies in multiple other indications. Dr. Rich received his Medical degree and Residency in Ophthalmology from the University of North Carolina at Chapel Hill.

Robert I. Goldfarb, B.A., J.D. – General Counsel

Mr. Goldfarb, Corporate Counsel and a member of the Board of Directors, has over twenty-five years of legal experience. Before joining SNS in December, 2011, Mr. Goldfarb was Senior Vice-President, General Counsel and Secretary of Andrx Corporation. Prior to that he was a partner with the law firm of Hughes, Hubbard and Reed. Mr. Goldfarb is presently President and General Counsel of Accu-Break Pharmaceuticals. He obtained his Bachelor’s degree from the University of Connecticut and his law degree from the University of Florida.

Michael Goodman, CPA – Chief Financial Officer

Michael Goodman, CPA, as Chief Financial Officer and member of the SNS Board of Directors, is a former Janover LLC, Managing Partner where he provided corporate structure services for over 35 years. Known throughout the public accounting community for his creativity, Michael’ s depth of knowledge has translated into effective corporate strategies. In assuming overall responsibility for managing the company’s finances, he will have direct involvement with financial planning, management of financial risks, and assist in all strategic and tactical matters relating to budget management, cost–benefit analysis, forecasting needs and securing of new funding. Michael is a member of the American Institute of CPAs and the New York State Society of CPAs. He has lectured widely throughout the country on taxation issues, and has been interviewed in a number of industry-related articles in leading publications. Prior to joining Janover, Michael practiced engineering in the aerospace industry, joining the development team at Grumman in designing the propulsion system of the lunar module. Michael earned his BS in Mechanical Engineering from Lehigh University, an MS in Mechanical Engineering from The City University of New York, and an MBA from Pace University.

Please Contact Us For Any Inquiries You May Have

©

Sustained Nano Systems, LLC. A New York LImited Liability Company